Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Core Insights - Nektar Therapeutics will announce its third-quarter financial results on November 6, 2025, after U.S. market close, with a conference call hosted by CEO Howard Robin at 5:00 p.m. Eastern Time [1] - The conference call will be accessible via a link on Nektar's website, with a replay available until December 6, 2025 [2] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently in two Phase 2b clinical trials for atopic dermatitis and alopecia areata, as well as a Phase 2 trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent TNFR2 antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified CSF protein NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3]